Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. - Wikidata - wikimedia - TriplyDB

Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.

Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.

http://www.wikidata.org/entity/Q30987490

about

Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.NAD+ augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling.Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2 SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents.β-Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.TonEBP suppresses IL-10-mediated immunomodulation.Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.Ortho-quinone-enhanced ascorbate oxidation. Combined roles of lipid charge and the magnesium cation.Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.Supramolecular interactions between β-lapachone with cyclodextrins studied using isothermal titration calorimetry and molecular modeling.Enhancing Oral Absorption of β-Lapachone: Progress Till Date.Reduction of doxorubicin-induced genotoxicity by Handroanthus impetiginosus in mouse bone marrow revealed by micronucleus assay.Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.Machine intelligence decrypts β-lapachone as an allosteric 5-lipoxygenase inhibitor

P2860

Q27346846-5CE15C71-6B32-4468-B9B8-C3818D1060D6 Q28539534-2FBD6B20-D11D-49CA-8D6A-1963029CC9CC Q33753357-304C2325-8B58-46F2-910D-599F038B7B10 Q33767952-F1D61BCC-E06C-4B4C-AADC-B3BBC17480B8 Q33774115-E31C05C2-CB2A-41F2-92F0-CDEEFABF76C9 Q34047248-02631B9E-157B-4B52-9DA2-FF9477943E8D Q35564075-4EE2C8DB-366A-415C-9642-E2F634CA0471 Q35593948-0C9803EB-E1A4-4C46-B9FF-6C05E88F4744 Q35852416-F89E5C97-722B-44DE-9028-7FFB60A63162 Q35880201-41D169FB-4F9F-44B9-AE50-93F70A8E1A10 Q36119847-EBCC9B50-DE29-4EEC-84BA-8CC93B82BA5A Q36695591-625D6FEF-A627-4EE5-A248-8306CA17426B Q36716649-2987CA91-76DD-4CE6-8A42-0C78CCDBB404 Q36886342-26CD8BD1-1B46-4D96-BE88-F88BD92CE2D9 Q37254021-4A5A2E26-BE5D-4D03-85DF-0CBBE5C52BF9 Q38603364-BC5BEB77-4C64-414E-A8A2-ADC497941BCE Q38919749-3568A69C-A9D9-4DB8-83D9-9D25EC784524 Q40296515-43493609-AA94-4280-A71F-30BA40A858A1 Q41855251-79C7C44E-E8F1-49F8-AC89-923DC86E067F Q42409402-8DDFEED7-1245-4445-8AB9-3EC007DBFB52 Q47793404-52F76264-71D7-49D3-BD6C-211EFAA56734 Q47984159-459605C7-7EC0-462A-9459-E7DBFF940CE5 Q49108416-C39578F8-A577-429C-95A6-8A9D28C692F1 Q50533614-50CF4E50-4F3F-4767-81F4-33AF64427EF7 Q51631401-C434FD68-40FC-48C1-8171-E9ECB5CFD91E Q57496141-3C550B38-A3DD-48C4-BEBC-E6BD5D9479F6

P2860

Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.

http://www.wikidata.org/entity/Q30987490

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Development of beta-lapachone ...... inone oxidoreductase 1 levels.

@ast

Development of beta-lapachone ...... inone oxidoreductase 1 levels.

@en

type

label

Development of beta-lapachone ...... inone oxidoreductase 1 levels.

@ast

Development of beta-lapachone ...... inone oxidoreductase 1 levels.

@en

prefLabel

Development of beta-lapachone ...... inone oxidoreductase 1 levels.

@ast

Development of beta-lapachone ...... inone oxidoreductase 1 levels.

@en

P1433

Q30987490-039F1A46-D3F5-49E2-ABE5-6D4EF332FB2E

P1476

Q30987490-140F60FF-B803-41B8-BFDB-590B25F7F4B2

P2093

Q30987490-1A001441-1BCC-424D-BA04-9286F0171B7F

Q30987490-1C044B62-CA67-4B8B-8F57-804C10F3A991

Q30987490-1ED05720-C53F-4717-9F87-0E6C91E99641

Q30987490-22ECDD49-3111-4744-A1B9-973AEC68C31A

Q30987490-36C5BB73-E56D-484B-B631-7290F38CE2DF

Q30987490-567E4CBB-AEDD-4678-A490-A0811BE5BA13

Q30987490-6768112D-7B27-4C2E-874C-5CCE2162A619

Q30987490-6F1C1B00-6F10-4F1D-BEE3-DD33B6718B04

Q30987490-799FE8A2-6C84-4E57-BF3B-1CAE13B6D990

Q30987490-8655E676-E7D7-409D-92A8-60A264014B83

P304

Q30987490-1728C125-893E-46F0-98EA-BA8AF65FCBDF

P31

Q30987490-D9F7884F-8FCE-445A-85CF-E548BB705575

P356

Q30987490-484C619B-B832-4581-AD5A-7DF161EA4F84

P407

Q30987490-59CFDDD4-DB86-455F-AF12-0A41D7CCF0D0

P433

Q30987490-AF7C7C66-2C40-405E-994E-5B9D712619A9

P478

Q30987490-20B4B3D2-4C10-4997-A93F-07AEA90296E6

P50

Q30987490-C7F58024-AE68-4E0B-9C65-D9B9A5317FB9

P577

Q30987490-908933E8-0F3B-4567-84FB-00659A6FB3A0

P698

Q30987490-107DD7FF-7D67-48A6-9598-FE781A3F8562

P356

1078-0432.CCR-04-2185

P1433

Clinical Cancer Research

P1476

Development of beta-lapachone ...... uinone oxidoreductase 1 levels

@en

P2093

Charles L Hoppel

http://www.w3.org/2001/XMLSchema#string

Damon Sutton

http://www.w3.org/2001/XMLSchema#string

David A Boothman

http://www.w3.org/2001/XMLSchema#string

Erik A Bey

http://www.w3.org/2001/XMLSchema#string

Gisela M Arzac

http://www.w3.org/2001/XMLSchema#string

Jinming Gao

http://www.w3.org/2001/XMLSchema#string

John J Pink

http://www.w3.org/2001/XMLSchema#string

Kathryn E Reinicke

http://www.w3.org/2001/XMLSchema#string

Melissa S Bentle

http://www.w3.org/2001/XMLSchema#string

Rosana I Misico

http://www.w3.org/2001/XMLSchema#string

P304

3055-3064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-04-2185

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15837761

http://www.w3.org/2001/XMLSchema#string